What is the recommended blood glucose target range for a non‑diabetic critically ill patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Glycemic Target in Non-Diabetic Critically Ill Patients

Primary Recommendation

For non-diabetic critically ill patients, initiate insulin therapy when blood glucose is ≥180 mg/dL (confirmed on two occasions) and target a glucose range of 140–180 mg/dL (7.8–10.0 mmol/L). 1, 2

Initiation Threshold

  • Start insulin therapy at blood glucose ≥180 mg/dL, confirmed on two separate measurements within 24 hours 1, 2
  • This threshold prevents prolonged hyperglycemia while avoiding the risks of overly aggressive early intervention 1
  • The trigger is intentionally set lower than the upper target limit to prevent sustained periods above the treatment range 1

Target Range: 140–180 mg/dL

The 140–180 mg/dL target is strongly supported by the NICE-SUGAR trial, which demonstrated that intensive glycemic control (targeting 81–108 mg/dL) resulted in significantly higher mortality (27.5% vs. 25%) and 10- to 15-fold greater rates of hypoglycemia compared to moderate targets 1

  • This moderate target range balances glycemic control benefits against hypoglycemia risk 1
  • Multiple meta-analyses confirm that tight glycemic control increases mortality compared to moderate targets 1
  • The Society of Critical Care Medicine 2024 guidelines endorse this same 140–180 mg/dL target for most critically ill adults 1

Special Consideration: Tighter Control for Selected Patients

For specific non-diabetic critically ill patients, a more stringent target of 110–140 mg/dL may be appropriate, but only if achievable without significant hypoglycemia 1, 2

Consider tighter control (110–140 mg/dL) for:

  • Critically ill postsurgical patients 1, 2
  • Patients following cardiac surgery 1, 2
  • Clinically stable patients with previous tight glycemic control 2

Critical caveat: This tighter range should only be pursued with validated protocols demonstrating low hypoglycemia rates 2

Why Non-Diabetic Patients Differ

Non-diabetic critically ill patients have distinctly different outcomes with glycemic control compared to diabetic patients:

  • Research demonstrates that non-diabetic patients with mean ICU glucose of 110–140 mg/dL had significantly lower mortality (7.3%) compared to those with 140–180 mg/dL (12.16%) 3
  • Non-diabetic patients who maintained time-in-range of 70–120 mg/dL for ≥40% of time had improved survival (7.0% mortality vs. 15.7%) 4
  • This mortality benefit was NOT observed in diabetic patients, suggesting non-diabetic patients may benefit from tighter control if safely achievable 4, 3
  • However, hypoglycemia and glucose variability are more strongly associated with mortality in non-diabetic patients than diabetic patients 3

Critical Safety Thresholds

Hypoglycemia prevention is paramount in non-diabetic critically ill patients:

  • Reassess and adjust insulin regimens when glucose falls below 100 mg/dL to prevent hypoglycemia 5, 2
  • Fasting glucose <100 mg/dL predicts hypoglycemia within the next 24 hours 1, 2
  • Never administer insulin when blood glucose is <70 mg/dL 5
  • Treat hypoglycemia <70 mg/dL immediately with 15–20 g fast-acting carbohydrate 5

Implementation Strategy

Use continuous intravenous insulin infusion with validated protocols:

  • IV insulin infusion is the most effective method for achieving glycemic targets in critical care 1
  • Protocols must demonstrate efficacy in achieving the 140–180 mg/dL target AND safety without increasing severe hypoglycemia risk 2
  • Frequent glucose monitoring every 30 minutes to 2 hours is mandatory during IV insulin therapy 1, 2
  • Point-of-care testing should use FDA-approved hospital-calibrated glucose monitoring systems 1

Common Pitfalls to Avoid

  • Do not target intensive control (<110 mg/dL) as routine practice – the NICE-SUGAR trial definitively showed harm 1
  • Do not ignore the higher mortality risk in non-diabetic patients with poor glycemic control – they may benefit more from moderate tightening (toward 110–140 mg/dL) than diabetic patients, if hypoglycemia can be avoided 4, 3
  • Do not allow glucose to exceed 180 mg/dL for prolonged periods – this causes immunosuppression and exceeds the renal threshold for glucosuria 1
  • Do not use sliding scale insulin alone – scheduled insulin regimens with validated protocols are required 1
  • Do not minimize dextrose infusions without considering other nutritional sources – avoid unnecessary glucose loads when patients receive alternative nutrition 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Glucose Management in Critically Ill Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5
Guideline

Target Non-Fasting Blood Sugar

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is it safe to increase my twice-daily basal insulin glargine (Lantus) from 15 units each dose to 20–25 units each dose in uncontrolled diabetes mellitus?
In diabetic patients, which individuals should receive low‑dose aspirin therapy?
How do I administer NovoMix 30 (insulin aspart protamine suspension) subcutaneously?
In a 39-year-old man with type 2 diabetes, post‑cardiac arrest, severe metabolic acidosis, and acute kidney injury on intermittent hemodialysis, is there any benefit to administering methylprednisolone?
In an 82-year-old patient with type 2 diabetes, multiple chronic comorbidities, and limited functional status, should aggressive glycemic control be recommended?
If a patient’s hair curl pattern changes (e.g., from 3C to 3A or 3C to 4B) due to micronutrient deficiencies, will correcting the deficiencies and normalizing iron, zinc, vitamin D, and biotin levels restore the original hair texture?
What is the optimal nephrology management plan for an adult patient with chronic kidney disease (serum creatinine ~1.6 mg/dL), a history of renal calculi, hypertension (blood pressure 140/90 mm Hg on amlodipine‑thiazide), hypertensive epistaxis, recent urinary‑tract infection, triglycerides 183 mg/dL, and current medications aspirin 75 mg daily and amlodipine‑thiazide?
What are the prevalence rates of iron deficiency anemia across different ethnicities and genders, and what screening and treatment recommendations apply?
What is the likely cause and recommended management for a female patient who experiences sudden deep anal canal pain/cramps when she strains during bowel movements?
How is choledocholithiasis classified?
How is orthostatic insufficiency diagnosed, is 24‑hour ambulatory blood pressure and heart‑rate monitoring required, and can a patient with postural tachycardia syndrome (POTS) who has tachycardia but normal blood pressure still be considered to have orthostatic insufficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question